Error reductions over time in Virgil eCOA versus paper-based administrations in psychiatry trials von Detke, M.J, Negash, S, Webber-Lind, B, Sorantin, P, Williams, J.B.W

Volltext

Poster #176 NSA-16 REVISITED: IDENTIFYING LATENT FACTORS OF NEGATIVE SYMPTOMS IN SCHIZOPHRENIA von Popp, D, Williams, JBW, Cohen, E.A, Detke, M.J

Volltext

P.2.b.027 A phase II randomized, double-blind, placebo-controlled trial of GLYX-13 for the rapid treatment of major depressive disorder (MDD) using central ratings von Popp, D, Burch, R, Williams, J.B.W, Price, L.M, Detke, M.J

Volltext

P.1.i.009 Some urban legends of CNS clinical trial methodology: unsuccessful solutions to the problem of failed trials von Williams, J.B.W, Popp, D, Reines, S, Detke, M.J

Volltext

Poster #177 THE USE OF THE NSA-16 BY VIDEOCONFERENCING IN A CLINICAL TRIAL von Williams, JBW, Popp, D, Osman, DA, Cohen, E.A, Detke, M.J

Volltext

P.8.b.004 Feasibility of centralised ratings for mental health safety screening in a dermatology trial von Williams, J.B.W, Popp, D, Price, L.M, Gross, J.A, Davis, D, Salvucci, D, Detke, M.J

Volltext

P.3.a.010 The use of the 16 item Negative Symptom Assessment (NSA-16) by videoconferencing in a clinical trial von Williams, J.B.W, Popp, D, Osman, D.A, Cohen, E.A, Detke, M.J

Volltext

674 MAINTENANCE OF EFFECT OF DULOXETINE IN PATIENTS WITH CHRONIC LOW BACK PAIN von Skljarevski, V., Zhang, S., Chappell, A.S., Detke, M.J., Murray, I., Backonja, M.

Volltext

P.2.f.028 - Error reductions over time in Virgil eCOA versus paper-based administrations in psychiatry trials von Detke, M.J., Negash, S., Webber-Lind, B., Sorantin, P., Williams, J.B.W.

Volltext

Non-Amyloid Approaches to Disease Modification for Alzheimer’s Disease: An EU/US CTAD Task Force Report von Gauthier, Serge, Aisen, P. S., Cummings, J., Detke, M. J., Longo, F. M., Raman, R., Sabbagh, M., Schneider, L., Tanzi, R., Tariot, P., Weiner, M., Touchon, J., Vellas, B.

Volltext

P.4.a.006 A fixed dose study of the efficacy and safety of duloxetine for the treatment of generalised anxiety disorder von Koponen, H., Allgulander, C., Pritchett, Y.L., Erickson, J., Detke, M.J., Ball, S., Russell, J.M.

Volltext

P.1.040 Efficacy of duloxetine treatment: Analysis of pooled data from six placebo- and SSRI-controlled clinical trials von Swindle, R.W., Mallinckrodt, C.H., Rosebaum, J.F., Lu, Y., Watkin, J.G., Ghandi, P., Detke, M.J.

Volltext

Design archetypes for phase 2 clinical trials in central nervous system disorders von Mallinckrodt, C.H, Detke, M.J, Prucka, W.R, Ruberg, S.J, Molenberghs, Geert

Volltext

Considerations for using positive controls in phase 2 clinical trials of central nervous system disorders von Mallinckrodt, C.H, Detke, M.J, Prucka, W.R, Ruberg, S.J, Molenberghs, Geert

Volltext

Considerations for Comparing a Test Drug With Standard of Care in Phase 2 Clinical Trials of Central Nervous System Disorders von Mallinckrodt, C.H, Detke, M.J, Prucka, W.R, Ruberg, S.J, Molenberghs, Geert

Volltext

Modulation of behavioral and insulin responses by contextual stimuli paired with food von Detke, Michael J., Brandon, S.E., Weingarten, Harvey P., Rodin, Judith, Wagner, Allan R.

Volltext

A phase 3 placebo-controlled study of galcanezumab in patients with treatment-resistant migraine: Results from the 3-month double-blind treatment phase of the conquer study von Mulleners, W., Kim, B., Láinez, M.J., Lanteri-Minet, M., Aurora, S.K., Nichols, R.M., Wang, S., Tockhorn-Heidenreich, A., Detke, H.

Volltext